CNS neuroscience & therapeutics · 2025
ARIP1 Deficiency Facilitates the Inhibition of Neuronal Ferroptosis in Cerebral Ischemia by Activin A Through SMAD3 and p38 MAPK Signaling.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zou Zhulin, Zhang Yunhan, Guo Chenmeng, Qie Xinyao, Xie Daqing, Wang Lerong, Liu Zhonghui, Liu Haiyan
Аннотация
INTRODUCTION: Ferroptosis is an essential pathophysiological process in cerebral ischemic injury. Activin receptor-interacting protein 1 (ARIP1) is a negative regulator of the activin signaling pathway in neurons.
OBJECTIVE: This study investigated whether activin A inhibits neuronal ferroptosis and the role of ARIP1 in cerebral ischemic injury.
METHODS AND RESULTS: In this study, activin A increased the viability of primary neurons under conditions of oxygen-glucose deprivation (OGD). Subsequent RNA-sequencing analysis of activin A-treated neurons identified expression of Slc7a11 as the ferroptosis-associated gene with significant upregulation. Next, using the CRISPR/Cas9 system, mice were generated with a heterozygous deficiency of ARIP1 (Arip1-/+), and the results revealed that the expression of GPX4 was markedly elevated and SLC7A11 was reduced in OGD-treated Arip1-/+ neurons, compared with that in wild-type (WT) neurons, which was accompanied by an increase of p-SMAD3 and a decrease of p-p38 MAPK levels. In addition, our data showed that activin A activated SMAD3 and inhibited p38 MAPK phosphorylation, which differentially modulated SLC7A11 and GPX4 expression, ultimately suppressing OGD-induced ferroptosis. Notably, Arip1-/+ mice showed an improvement in neurological deficits and reduced cerebral infarction in the permanent middle cerebral artery occlusion (pMCAO) model. Furthermore, we observed that activin A exerted similar protective effects against ischemic injury in Arip1-/+ mice.
CONCLUSION: These findings indicate that downregulating the expression of ARIP1 suppresses neuronal ferroptosis by modulating SLC7A11/GPX4 expression via SMAD3 and p38 MAPK signaling, ultimately enhancing the neuroprotective role of activin A against cerebral ischemia.
OBJECTIVE: This study investigated whether activin A inhibits neuronal ferroptosis and the role of ARIP1 in cerebral ischemic injury.
METHODS AND RESULTS: In this study, activin A increased the viability of primary neurons under conditions of oxygen-glucose deprivation (OGD). Subsequent RNA-sequencing analysis of activin A-treated neurons identified expression of Slc7a11 as the ferroptosis-associated gene with significant upregulation. Next, using the CRISPR/Cas9 system, mice were generated with a heterozygous deficiency of ARIP1 (Arip1-/+), and the results revealed that the expression of GPX4 was markedly elevated and SLC7A11 was reduced in OGD-treated Arip1-/+ neurons, compared with that in wild-type (WT) neurons, which was accompanied by an increase of p-SMAD3 and a decrease of p-p38 MAPK levels. In addition, our data showed that activin A activated SMAD3 and inhibited p38 MAPK phosphorylation, which differentially modulated SLC7A11 and GPX4 expression, ultimately suppressing OGD-induced ferroptosis. Notably, Arip1-/+ mice showed an improvement in neurological deficits and reduced cerebral infarction in the permanent middle cerebral artery occlusion (pMCAO) model. Furthermore, we observed that activin A exerted similar protective effects against ischemic injury in Arip1-/+ mice.
CONCLUSION: These findings indicate that downregulating the expression of ARIP1 suppresses neuronal ferroptosis by modulating SLC7A11/GPX4 expression via SMAD3 and p38 MAPK signaling, ultimately enhancing the neuroprotective role of activin A against cerebral ischemia.